Patents Assigned to Laboratories Serono SA
-
Publication number: 20100021429Abstract: The present invention relates to the use of multiple doses of Cladribine combined with beta interferon for the treatment of multiple sclerosis in patients who are refractory to at least one conventional therapy.Type: ApplicationFiled: May 23, 2007Publication date: January 28, 2010Applicant: LABORATORIES SERONO SAInventors: H. James Brentzel, JR., Maria Lopez-Bresnahan, Nazih Ammoury
-
Patent number: 7598046Abstract: The use of Apolipoprotein B, Apolipoprotein E, fragments and mimetics thereof is provided for diagnostic, detection, prognostic and therapeutic applications In prion diseases. More specifically, the invention provides the use of Apolipoprotein B or fragments thereof for modulating or identifying modulators of the prion protein replication which are implicated in the pathogenesis of transmissible spongiform encephalopathics and other prion diseases.Type: GrantFiled: June 18, 2004Date of Patent: October 6, 2009Assignee: Laboratories Serono SAInventors: Claudio Soto-Jara, Kinsey Maundrell
-
Publication number: 20090176761Abstract: This invention relates to a method of treating and/or preventing endometriosis comprising administering a JNK inhibitor. The JNK inhibitor can also be administered combined with a hormonal suppressor.Type: ApplicationFiled: July 12, 2006Publication date: July 9, 2009Applicant: LABORATORIES SERONO SAInventors: Stephen S. Palmer, Selvaraj Nataraja
-
Publication number: 20090169506Abstract: The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.Type: ApplicationFiled: December 16, 2008Publication date: July 2, 2009Applicant: LABORATORIES SERONO SAInventors: Michel DREANO, Pierre-Alain Vitte
-
Publication number: 20080306057Abstract: This invention relates to a method of treating and/or preventing endometriosis comprising administering a PI3K inhibitor. The PI3K inhibitor can also be administered combined with a hormonal suppressor. The invention further relates to the treatment of endometriosis-related infertility.Type: ApplicationFiled: August 28, 2006Publication date: December 11, 2008Applicant: LABORATORIES SERONO SAInventors: Stephen Palmer, Selvaraj Nataraja
-
Publication number: 20080253996Abstract: The invention relates to the use of SDF-1, or of an agonist of SDF-1 activity, for the treatment and/or prevention of a neurological disease.Type: ApplicationFiled: October 30, 2006Publication date: October 16, 2008Applicant: LABORATORIES SERONO SAInventors: Ursula Boschert, Amanda Proudfoot, Linda Kadi, Pierre Alain Vitte, Jerome Wojcik
-
Patent number: 7432286Abstract: The present invention is related to sulfonyl hydrazide derivatives for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonyl hydrazide derivatives. Said sulfonyl hydrazide derivatives are efficient modulators of the JNK pathway, they are in particular efficient inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonyl hydrazide derivatives as well as to methods of their preparation.Type: GrantFiled: September 28, 2000Date of Patent: October 7, 2008Assignee: Laboratories Serono SAInventors: Stephen Arkinstall, Serge Halazy, Dennis Church, Montserrat Camps, Thomas Rueckle, Jean-Pierre Gotteland, Marco Biamonte
-
Publication number: 20080221180Abstract: The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.Type: ApplicationFiled: May 24, 2006Publication date: September 11, 2008Applicant: LABORATORIES SERONO SAInventors: Anna Quattropani, David Covini, Vincent Pomel, Jerome Dorbais, Thomas Rueckle
-
Publication number: 20080207722Abstract: The present invention is related to the use of a Glepp-1 inhibitor for the manufacture of a medicament for the treatment of an autoimmune and/or an inflammatory disorder.Type: ApplicationFiled: July 14, 2006Publication date: August 28, 2008Applicant: LABORATORIES SERONO SAInventors: Agnes Bombrun, Rob Hooft Van Huijsduijnen, Catherine Jorand-Lebrun, Pierre-Alain Vitte, Patrick Gerber
-
Patent number: 7405197Abstract: The invention provides a protocol leading to improved embryo implantation rates and/or decreased miscarriage rates in which hCG, or a bio-analogue, is administered during the follicular phase.Type: GrantFiled: September 12, 2002Date of Patent: July 29, 2008Assignee: Laboratories Serono SAInventor: Yves Menezo
-
Publication number: 20080107627Abstract: The invention relates to the use of SARP-1 for the preparation of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis.Type: ApplicationFiled: December 20, 2007Publication date: May 8, 2008Applicant: LABORATORIES SERONO SAInventors: Christine PLATER-ZYBERK, Christine Power, Jacques Colinge
-
Patent number: 7351526Abstract: A method for the diagnosis or detection of conformational diseases by assaying for a marker (the pathogenic conformer) of such diseases in a sample is described, which method comprises a cyclic amplification system to increase the levels of the pathogenic conformer which causes such diseases. In particular, such transmissible conformational diseases may be prion encephalopathies. Assays, diagnostic kits and apparatus based on such methods are also disclosed.Type: GrantFiled: June 13, 2001Date of Patent: April 1, 2008Assignee: Laboratories Serono SAInventors: Claudio Soto, Gabriella Saborio
-
Patent number: 7344709Abstract: The present invention relates to the use of recombinant IFN-beta for the production of a medicament for the treatment of HCV infection by subcutaneous administration to patients of Asian race, which failed to respond to a previous treatment with interferon-alpha, is herein reported. According to a preferred embodiment of the invention, this treatment can be better and further focused to those patients which after at least 4 weeks of initial treatment with IFN-beta show HCV RNA clearance.Type: GrantFiled: May 28, 2003Date of Patent: March 18, 2008Assignee: Laboratories Serono SAInventors: Ian Parsons, Theodor Wee Tit Gin, Birgit Maschek
-
Patent number: 7314878Abstract: The present invention is related to piperazine henzothiazole derivatives, notably for use in the treatment and/or prophylaxis of cerebral ischemic disorders or CNS disorders. The present invention is furthermore related to methods of their preparation.Type: GrantFiled: April 25, 2003Date of Patent: January 1, 2008Assignee: Laboratories Serono SAInventors: Pascale Gaillard, Jean-Pierre Gotteland, Pierre-Alain Vitte
